Stock NVNO ENVVENO MEDICAL CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

News enVVeno Medical Corporation

Equities

NVNO

US29415J1060

Real-time Estimate Cboe BZX
Other stock markets
 11:13:07 2024-06-20 EDT 		5-day change 1st Jan Change
4.75 USD +1.06% Intraday chart for enVVeno Medical Corporation 0.00% -8.17%
06-17 EnVVeno Medical Corporation Announces New Interim Venous Ulcer Healing Data from the VenoValve®? Pivotal Trial to Be Presented at the Society for Vascular Surgery 2024 Vascular Annual Meeting CI
05-08 EnVVeno Medical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
New Interim Venous Ulcer Healing Data from the enVVeno Medical VenoValve Pivotal Trial to be Presented at the Society for Vascular Surgery 2024 Vascular Annual Meeting on June 21, 2024
AQ
EnVVeno Medical Corporation Announces New Interim Venous Ulcer Healing Data from the VenoValve®? Pivotal Trial to Be Presented at the Society for Vascular Surgery 2024 Vascular Annual Meeting
CI
EnVVeno Medical Reports First Quarter 2024 Financial Results and Provides Corporate Update
AQ
EnVVeno Medical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Positive 11 Month Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical's VenoValve Pivotal Trial to be Presented Today at the 46th Annual Charing Cross Symposium
AQ
New Topline Efficacy Data from the enVVeno Medical VenoValve Pivotal Trial to be presented at the 46th Annual Charing Cross Symposium on April 24, 2024
AQ
EnVVeno Medical Corporation Announces Additional Topline Efficacy Data from the VenoValve U.S. Pivotal Trial to Be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024
CI
EnVVeno Medical Appoints Andrew Cormack as Its Chief Commercial Officer
AQ
EnVVeno Medical : Corporate Presentation
PU
EnVVeno Medical Corporation Appoints Andrew Cormack as Its Chief Commercial Officer
CI
EnVVeno Medical : Corporate Presentation
PU
Positive Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical's VenoValve Pivotal Trial to be Presented Today at the VENOUS2024 American Venous Forum Annual Meeting
AQ
EnVVeno Announces Positive Topline Efficacy Data for VenoValve US Pivotal Trial
MT
EnVVeno Medical Corporation Announces the Presentation of Positive Topline Efficacy Data Showing Significant Clinical Improvement from the Savve U.S. Pivotal Trial for the Venovalve
CI
EnVVeno Medical : Corporate Presentation
PU
EnVVeno Medical Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
AQ
EnVVeno Medical Corporation Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Topline Efficacy Data from the enVVeno Medical VenoValve Pivotal Trial to be presented at the VENOUS2024 American Venous Forum Annual Meeting on March 6, 2024
AQ
EnVVeno Medical Posts Company Highlights and Materials from 2023 VEITH Symposium
AQ
EnVVeno Medical Presents Positive Preliminary Device Related Material Adverse Event Data from the VenoValve Pivotal Trial at the 50th Annual VEITH Symposium
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NVNO Stock
  4. News enVVeno Medical Corporation